Dual GIP/GLP-1 receptor agonist for powerful appetite suppression and metabolic improvement
Review Required
No source PDF found. This guide was created from the Matrix seed list only. All dosing is inferred from standard clinical protocols and requires full prescriber review.
Tirzepatide is a dual-agonist targeting both GIP and GLP-1 receptors. It provides powerful appetite suppression and broad metabolic improvement, representing the dual-agonist tier between single-agonist semaglutide and triple-agonist retatrutide.
Activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptors. The dual pathway delivers stronger appetite suppression and metabolic improvement than GLP-1-only compounds, with enhanced insulin sensitivity and fat metabolism.
| Parameter | Details |
|---|---|
| Starting Dose | 2.5 mg weekly |
| Titration | Increase 2.5 mg every 4 weeks |
| Target Dose | 5–15 mg weekly |
| Frequency | Once weekly |
| Route | Subcutaneous (SubQ) injection |
Review Required
All dosing above is inferred from standard clinical protocols. Full Matrix-specific protocol requires prescriber review and confirmation.
Do Not Stack
Do not stack with other GLP-1 receptor agonists.
FDA Black-Box Warning
FDA black-box warning exists across the entire GLP-1 class regarding thyroid C-cell tumors observed in rodent studies. No confirmed human signal. Prescriber authorization required.
Clinical Note
Monitor body composition, blood glucose, lipid panel, and GI tolerance. Prescriber authorization required for dose changes.
This guide is for educational and clinical-support purposes only. All dosing must be supervised by a licensed prescriber. Matrix Advanced Solutions does not provide medical advice. Always consult your healthcare provider before starting any peptide protocol.